Blood Reviews
Volume 17, Issue 1 , Pages 15-23 , March 2003

Molecular targets in acute myelogenous leukemia

  • Derek L Stirewalt

      Affiliations

    • Clinical Research Division, Fred Hutchinson Cancer Research Center, The Division of Oncology, University of Washington, Seattle, WA, USA
    • Corresponding Author InformationCorrespondence to: Derek L. Stirewalt, M.D., Fred Hutchinson Cancer Research Center, D4-100, 1100 Fairview Avenue, North Seattle, WA 98109, USA. Tel.: 1-206-667-5113; Fax: 1-206-667-2917
    • ,
  • Soheil Meshinchi

      Affiliations

    • Clinical Research Division, Fred Hutchinson Cancer Research Center, The Division of Oncology, University of Washington, Seattle, WA, USA
    • Department of Pediatrics, University of Washington, Seattle, WA, USA
    • ,
  • Jerald P Radich

      Affiliations

    • Clinical Research Division, Fred Hutchinson Cancer Research Center, The Division of Oncology, University of Washington, Seattle, WA, USA

References 

  1. Palmero I, Pantoja C, Serrano M. p19ARF links the tumour suppressor p53 to RAS. Nature. 1998;395:125–126
  2. Hayakawa F, Towatari M, Kiyoi H, et al.  Tandem-duplicated Flt3 constitutively activates STAT5 and MAP kinase and introduces autonomous cell growth in IL-3-dependent cell lines. Oncogene. 2000;19:624–631
  3. Mizuki M, Fenski R, Halfter H, et al.  Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways. Blood. 2000;96:3907–3914
  4. Delgado MD, Vaque JP, Arozarena I, et al.  H-, K- and N-Ras inhibit myeloid leukemia cell proliferation by a p21WAF1-dependent mechanism. Oncogene. 2000;19:783–790
  5. Kelly LM, Yu J, Boulton CL, et al.  CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML). Caner Cell. 2002;
  6. Boettner B, Van Aelst L. The role of Rho GTPases in disease development. Gene. 2002;286:155–174
  7. Byrne JL, Marshall CJ. The molecular pathophysiology of myeloid leukaemias: Ras revisited. Br. J. Haematol. 1998;100:256–264
  8. Boguski MS, McCormick F. Proteins regulating Ras and its relatives. Nature. 1993;366:643–654
  9. Gilliland DG, Griffin JD. Role of FLT3 in leukemia. Curr. Opin. Hematol. 2002;9:274–281
  10. Bos JL. Ras oncogenes in human cancer: a review. Cancer Res. 1989;49:4682–4689
  11. Aaronson SA. Growth factors and cancer. Science. 1991;254:1146–1153
  12. Agnes F, Shamoon B, Dina C, et al.  Genomic structure of the downstream part of the human FLT3 gene: exon/intron structure conservation among genes encoding receptor tyrosine kinases (RTK) of subclass III. Gene. 1994;145:283–288
  13. Broudy VC. Stem cell factor and hematopoiesis. Blood. 1997;90:1345–1364
  14. Rosnet O, Marchetto S, deLapeyriere O, et al.  Murine Flt3, a gene encoding a novel tyrosine kinase receptor of the PDGFR/CSF1R family. Oncogene. 1991;6:1641–1650
  15. Small D, Levenstein M, Kim E, et al.  STK-1, the human homolog of Flk-2/Flt-3, is selectively expressed in CD34+ human bone marrow cells and is involved in the proliferation of early progenitor/stem cells. Proc. Natl. Acad. Sci. USA. 1994;91:459–463
  16. Gelb MH. Protein prenylation, et cetera: signal transduction in two dimensions. Science. 1997;275:1750–1751
  17. Koblan KS, Kohl NE, Omer CA, et al.  Farnesyltransferase inhibitors: a new class of cancer chemotherapeutics. Biochem. Soc. Trans. 1996;24:688–692
  18. Zhang S, Mantel C, Broxmeyer HE. Flt3 signaling involves tyrosyl-phosphorylation of SHP-2 and SHIP and their association with Grb2 and Shc in Baf3/Flt3 cells. J. Leukoc. Biol. 1999;65:372–380
  19. Lennartsson J, Blume-Jensen P, Hermanson M, et al.  Phosphorylation of Shc by Src family kinases is necessary for stem cell factor receptor/c-kit mediated activation of the Ras/MAP kinase pathway and c-fos induction. Oncogene. 1999;18:5546–5553
  20. Kang CD, Do IR, Kim KW, et al.  Role of Ras/ERK-dependent pathway in the erythroid differentiation of K562 cells. Exp. Mol. Med. 1999;31:76–82
  21. Katz ME, McCormick F. Signal transduction from multiple Ras effectors. Curr. Opin. Genet. Dev. 1997;7:75–79
  22. Kauffmann-Zeh A, Rodriguez-Viciana P, Ulrich E, et al.  Suppression of c-Myc-induced apoptosis by Ras signalling through PI(3)K and PKB. Nature. 1997;385:544–548
  23. Khosravi-Far R, White MA, et al.  Oncogenic Ras activation of Raf/mitogen-activated protein kinase-independent pathways is sufficient to cause tumorigenic transformation. Mol. Cell Biol. 1996;16:3923–3933
  24. Kishida S, Koyama S, Matsubara K, et al.  Colocalization of Ras and Ral on the membrane is required for Ras-dependent Ral activation through Ral GDP dissociation stimulator. Oncogene. 1997;15:2899–2907
  25. Clark GJ, Westwick JK, Der CJ. p120 GAP modulates Ras activation of Jun kinases and transformation. J. Biol. Chem. 1997;272:1677–1681
  26. Moodie SA, Willumsen BM, Weber MJ, et al.  Complexes of Ras. GTP with Raf-1 and mitogen-activated protein kinase kinase. Science. 1993;260:1658–1661
  27. Lange-Carter CA, Pleiman CM, Gardner AM, et al.  A divergence in the MAP kinase regulatory network defined by MEK kinase and Raf. Science. 1993;260:315–319
  28. Zhao Y, Bjorbaek C, Moller DE. Regulation and interaction of pp90(rsk) isoforms with mitogen-activated protein kinases. J. Biol. Chem. 1996;271:29773–29779
  29. Willard FS, Crouch MF. MEK, ERK, and p90RSK are present on mitotic tubulin in Swiss 3T3 cells: a role for the MAP kinase pathway in regulating mitotic exit. Cell Signal. 2001;13:653–664
  30. Olson MF, Ashworth A, Hall A. An essential role for Rho, Rac, and Cdc42 GTPases in cell cycle progression through G1. Science. 1995;269:1270–1272
  31. Ihle JN. Signaling by the cytokine receptor superfamily in normal and transformed hematopoietic cells. Adv. Cancer Res. 1996;68:23–65
  32. Taniguchi T. Cytokine signaling through nonreceptor protein tyrosine kinases. Science. 1995;268:251–255
  33. Rane SG, Reddy EP. JAKs, STATs and Src kinases in hematopoiesis. Oncogene. 2002;21:3334–3358
  34. Ridge SA, Worwood M, Oscier D, et al.  FMS mutations in myelodysplastic, leukemic, and normal subjects. Proc. Natl. Acad. Sci. USA. 1990;87:1377–1380
  35. Tobal K, Pagliuca A, Bhatt B, et al.  Mutation of the human FMS gene (M-CSF receptor) in myelodysplastic syndromes and acute myeloid leukemia. Leukemia. 1990;4:486–489
  36. Padua RA, Guinn BA, Al-Sabah AI, et al.  RAS, FMS and p53 mutations and poor clinical outcome in myelodysplasias: a 10-year follow-up. Leukemia. 1998;12:887–892
  37. Gari M, Goodeve A, Wilson G, et al.  c-kit proto-oncogene exon 8 in-frame deletion plus insertion mutations in acute myeloid leukaemia. Br. J. Haematol. 1999;105:894–900
  38. Sperr WR, Walchshofer S, Horny HP, et al.  Systemic mastocytosis associated with acute myeloid leukaemia: report of two cases and detection of the c-kit mutation Asp-816 to Val. Br. J. Haematol. 1998;103:740–749
  39. Nakao M, Yokota S, Iwai T, et al.  Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. Leukemia. 1996;10:1911–1918
  40. Kiyoi H, Towatari M, Yokota S, et al.  Internal tandem duplication of the FLT3 gene is a novel modality of elongation mutation which causes constitutive activation of the product. Leukemia. 1998;12:1333–1337
  41. Kiyoi H, Naoe T, Yokota S, et al.  Internal tandem duplication of FLT3 associated with leukocytosis in acute promyelocytic leukemia. Leukemia Study Group of the Ministry of Health and Welfare (Kohseisho). Leukemia. 1997;11:1447–1452
  42. Xu F, Taki T, Yang HW, et al.  Tandem duplication of the FLT3 gene is found in acute lymphoblastic leukaemia as well as acute myeloid leukaemia but not in myelodysplastic syndrome or juvenile chronic myelogenous leukaemia in children. Br. J. Haematol. 1999;105:155–162
  43. Yokota S, Kiyoi H, Nakao M, et al.  Internal tandem duplication of the FLT3 gene is preferentially seen in acute myeloid leukemia and myelodysplastic syndrome among various hematological malignancies. A study on a large series of patients and cell lines. Leukemia. 1997;11:1605–1609
  44. Stirewalt DL, Kopecky KJ, Meshinchi S, et al.  FLT3, RAS, and TP53 mutations in elderly patients with acute myeloid leukemia. Blood. 2001;97:3589–3595
  45. Meshinchi S, Woods WG, Stirewalt DL, et al.  Prevalence and prognostic significance of FLT3 internal tandem duplication in pediatric acute myeloid leukemia. Blood. 2001;97:89–94
  46. Iwai T, Yokota S, Nakao M, et al.  Internal tandem duplication of the FLT3 gene and clinical evaluation in childhood acute myeloid leukemia. The Children’s Cancer and Leukemia Study Group, Japan. Leukemia. 1999;13:38–43
  47. Schnittger S, Schoch C, Dugas M, et al.  Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease. Blood. 2002;100:59–66
  48. Thiede C, Steudel C, Mohr B, et al.  Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood. 2002;99:4326–4335
  49. Abu-Duhier FM, Goodeve AC, Wilson GA, et al.  FLT3 internal tandem duplication mutations in adult acute myeloid leukaemia define a high-risk group. Br. J. Haematol. 2000;111:190–195
  50. Lyman SD. Biology of flt3 ligand and receptor. Int. J. Hematol. 1995;62:63–73
  51. Lisovsky M, Estrov Z, Zhang X, et al.  Flt3 ligand stimulates proliferation and inhibits apoptosis of acute myeloid leukemia cells: regulation of Bcl-2 and Bax. Blood. 1996;88:3987–3997
  52. Yamamoto Y, Kiyoi H, Nakano Y, et al.  Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. Blood. 2001;97:2434–2439
  53. Abu-Duhier FM, Goodeve AC, Wilson GA, et al.  Identification of novel FLT-3 Asp835 mutations in adult acute myeloid leukaemia. Br. J. Haematol. 2001;113:983–988
  54. Kelly LM, Liu Q, Kutok JL, et al.  FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model. Blood. 2002;99:310–318
  55. Kelly LM, Kutok JL, Williams IR, et al.  PML/RARα and FLT3-ITD induce an APL-like disease in a mouse model. Proc. Natl. Acad. Sci. USA. 2002;99:8283–8288
  56. Farr CJ, Saiki RK, Erlich HA, et al.  Analysis of RAS gene mutations in acute myeloid leukemia by polymerase chain reaction and oligonucleotide probes. Proc. Natl. Acad. Sci. USA. 1988;85:1629–1633
  57. Bartram CR, Ludwig WD, Hiddemann W, et al.  Acute myeloid leukemia: analysis of ras gene mutations and clonality defined by polymorphic X-linked loci. Leukemia. 1989;3:247–256
  58. Radich JP, Kopecky KJ, Willman CL, et al.  N-ras mutations in adult de novo acute myelogenous leukemia: prevalence and clinical significance. Blood. 1990;76:801–807
  59. Bos JL, Verlaan-de Vries M, van der Eb AJ, et al.  Mutations in N-ras predominate in acute myeloid leukemia. Blood. 1987;69:1237–1241
  60. Vogelstein B, Civin CI, Preisinger AC, et al.  RAS gene mutations in childhood acute myeloid leukemia: a Pediatric Oncology Group study. Genes Chromosomes Cancer. 1990;2:159–162
  61. Neubauer A, Dodge RK, George SL, et al.  Prognostic importance of mutations in the ras proto-oncogenes in de novo acute myeloid leukemia. Blood. 1994;83:1603–1611
  62. Paquette RL, Landaw EM, Pierre RV, et al.  N-ras mutations are associated with poor prognosis and increased risk of leukemia in Myelodysplasia Syndrome. Blood. 1993;82:590–599
  63. Miyauchi J, Asada M, Sasaki M, et al.  Mutations of the N-ras gene in juvenile chronic myelogenous leukemia. Blood. 1994;83:2248–2254
  64. Flotho C, Valcamonica S, Mach-Pascual S, et al.  RAS mutations and clonality analysis in children with juvenile myelomonocytic leukemia (JMML). Leukemia. 1999;13:32–37
  65. Hirsch-Ginsberg C, LeMaistre AC, Kantarjian H, et al.  RAS mutations are rare events in Philadelphia chromosome-negative/bcr gene rearrangement-negative chronic myelogenous leukemia, but are prevalent in chronic myelomonocytic leukemia. Blood. 1990;76:1214–1219
  66. Collins SJ, Howard M, Andrews DF, et al.  Rare occurrence of N-ras point mutations in Philadelphia chromosome positive chronic myeloid leukemia. Blood. 1989;73:1028–1032
  67. Towatari M, Iida H, Tanimoto M, et al.  Constitutive activation of mitogen-activated protein kinase pathway in acute leukemia cells. Leukemia. 1997;11:479–484
  68. Lida M, Towatari M, Nakao A, et al.  Lack of constitutive activation of MAP kinase pathway in human acute myeloid leukemia cells with N-Ras mutation. Leukemia. 1999;13:585–589
  69. Morgan MA, Dolp O, Reuter CW. Cell-cycle-dependent activation of mitogen-activated protein kinase kinase (MEK-1/2) in myeloid leukemia cell lines and induction of growth inhibition and apoptosis by inhibitors of RAS signaling. Blood. 2001;97:1823–1834
  70. Serrano M, Lin AW, McCurrach ME, et al.  Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell. 1997;88:593–602
  71. Birkenkamp KU, Geugien M, Lemmink HH, et al.  Regulation of constitutive STAT5 phosphorylation in acute myeloid leukemia blasts. Leukemia. 2001;15:1923–1931
  72. Schuringa JJ, Wierenga AT, Kruijer W, et al.  Constitutive Stat3, Tyr705, and Ser727 phosphorylation in acute myeloid leukemia cells caused by the autocrine secretion of interleukin-6. Blood. 2000;95:3765–3770
  73. Ning ZQ, Li J, Arceci RJ. Signal transducer and activator of transcription 3 activation is required for Asp(816) mutant c-Kit-mediated cytokine-independent survival and proliferation in human leukemia cells. Blood. 2001;97:3559–3567
  74. Peeters P, Raynaud SD, Cools J, et al.  Fusion of TEL, the ETS-variant gene 6 (ETV6), to the receptor-associated kinase JAK2 as a result of t(9;12) in a lymphoid and t(9;15;12) in a myeloid leukemia. Blood. 1997;90:2535–2540
  75. Lacronique V, Boureux A, Valle VD, et al.  A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia. Science. 1997;278:1309–1312
  76. Pendergast AM, Quilliam LA, Cripe LD, et al.  BCR–ABL-induced oncogenesis is mediated by direct interaction with the SH2 domain of the GRB-2 adaptor protein. Cell. 1993;75:175–185
  77. Golub TR, Barker GF, Lovett M, et al.  Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation. Cell. 1994;77:307–316
  78. Fenski R, Flesch K, Serve S, et al.  Constitutive activation of FLT3 in acute myeloid leukaemia and its consequences for growth of 32D cells. Br. J. Haematol. 2000;108:322–330
  79. Druker BJ, Lydon NB. Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia. J. Clin. Invest. 2000;105:3–7
  80. Carroll M, Ohno-Jones S, Tamura S, et al.  CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR–ABL, TEL–ABL, and TEL–PDGFR fusion proteins. Blood. 1997;90:4947–4952
  81. Druker BJ, Sawyers CL, Kantarjian H, et al.  Activity of a specific inhibitor of the BCR–ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N. Engl. J. Med. 2001;344:1038–1042
  82. Heinrich MC, Griffith DJ, Druker BJ, et al.  Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood. 2000;96:925–932
  83. Beghini A, Cairoli R, Morra E, et al.  In vivo differentiation of mast cells from acute myeloid leukemia blasts carrying a novel activating ligand-independent C-kit mutation. Blood Cells Mol. Dis. 1998;24:262–270
  84. Ma Y, Zeng S, Metcalfe DD, et al.  The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations. Blood. 2002;99:1741–1744
  85. Smolich BD, Yuen HA, West KA, et al.  The antiangiogenic protein kinase inhibitors SU5416 and SU6668 inhibit the SCF receptor (c-kit) in a human myeloid leukemia cell line and in acute myeloid leukemia blasts. Blood. 2001;97:1413–1421
  86. Mesters RM, Padro T, Bieker R, et al.  Stable remission after administration of the receptor tyrosine kinase inhibitor SU5416 in a patient with refractory acute myeloid leukemia. Blood. 2001;98:241–243
  87. Kuenen BC, Rosen L, Smit EF, et al.  Dose-finding and pharmacokinetic study of cisplatin, gemcitabine, and SU5416 in patients with solid tumors. J. Clin. Oncol. 2002;20:1657–1667
  88. Mackarehtschian K, Hardin JD, Moore KA, et al.  Targeted disruption of the flk2/flt3 gene leads to deficiencies in primitive hematopoietic progenitors. Immunity. 1995;3:147–161
  89. Zhao M, Kiyoi H, Yamamoto Y, et al.  In vivo treatment of mutant FLT3-transformed murine leukemia with a tyrosine kinase inhibitor. Leukemia. 2000;14:374–378
  90. Tse KF, Novelli E, Civin CI, et al.  Inhibition of FLT3-mediated transformation by use of a tyrosine kinase inhibitor. Leukemia. 2001;15:1001–1010
  91. Levis M, Tse KF, Smith BD, et al.  A FLT3 tyrosine kinase inhibitor is selectively cytotoxic to acute myeloid leukemia blasts harboring FLT3 internal tandem duplication mutations. Blood. 2001;98:885–887
  92. Allebach J, Levis M, Fai-Tse K, et al.  FLT3-targeted tyrosine kinase inhibitors inhibit proliferation, induce apoptosis, and improve survival in a murine leukemia model utilizing FLT3/ITD-transformed cells. Blood. 2001;89:118a
  93. Levis M, Allebach J, Tse KF, et al.  A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo. Blood. 2002;99:3885–3891
  94. Levis M, Allebach J, Fai-Tse K, et al.  FLT3-targeted inhibitors kill FLT3-dependent modeled cells, leukemia-derived cell lines, and primary AML blasts in vitro and in vivo. Blood. 2001;89:721a
  95. Yee KWH, O’Farrell A, Smolich BD, et al.  SU5416 and SU5614 inhibit wild-type and activated mutant FLT3 signaling in leukemia cells. Blood. 2001;89:
  96. O’Farrell A, Abrams T, Yuen H, et al.  Sugen compounds SU5416 and SU11248 inhibit Flt3 activity: therapeutic application in AML. Blood. 2001;89:118a
  97. Weisberg E, Boulton C, Kelly LM, et al.  Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412. Cancer Cell. 2002;1:433–443
  98. Lerner EC, Qian Y, Blaskovich MA, et al.  Ras CAAX peptidomimetic FTI-277 selectively blocks oncogenic Ras signaling by inducing cytoplasmic accumulation of inactive Ras–Raf complexes. J. Biol. Chem. 1995;270:26802–26806
  99. Cox AD, Garcia AM, Westwick JK, et al.  The CAAX peptidomimetic compound B581 specifically blocks farnesylated, but not geranylgeranylated or myristylated, oncogenic ras signaling and transformation. J. Biol. Chem. 1994;269:19203–19206
  100. Miquel K, Pradines A, Sun J, et al.  GGTI-298 induces G0-G1 block and apoptosis whereas FTI-277 causes G2-M enrichment in A549 cells. Cancer Res. 1997;57:1846–1850
  101. Sepp-Lorenzino L, Rosen N. A farnesyl-protein transferase inhibitor induces p21 expression and G1 block in p53 wild type tumor cells. J. Biol. Chem. 1998;273:20243–20251
  102. Sun J, Qian Y, Hamilton AD, et al.  Ras CAAX peptidomimetic FTI 276 selectively blocks tumor growth in nude mice of a human lung carcinoma with K-Ras mutation and p53 deletion. Cancer Res. 1995;55:4243–4247
  103. Sun J, Qian Y, Hamilton AD, et al.  Both farnesyltransferase and geranylgeranyltransferase I inhibitors are required for inhibition of oncogenic K-Ras prenylation but each alone is sufficient to suppress human tumor growth in nude mouse xenografts. Oncogene. 1998;16:1467–1473
  104. Sepp-Lorenzino L, Ma Z, Rands E, et al.  A peptidomimetic inhibitor of farnesyl:protein transferase blocks the anchorage-dependent and -independent growth of human tumor cell lines. Cancer Res. 1995;55:5302–5309
  105. Prendergast GC, Davide JP, deSolms SJ, et al.  Farnesyltransferase inhibition causes morphological reversion of ras-transformed cells by a complex mechanism that involves regulation of the actin cytoskeleton. Mol. Cell. Biol. 1994;14:4193–4202
  106. Oliff A. Farnesyltransferase inhibitors: targeting the molecular basis of cancer. Biochim. Biophys. Acta. 1999;1423:C19–C30
  107. Lebowitz PF, Prendergast GC. Non-Ras targets of farnesyltransferase inhibitors: focus on Rho. Oncogene. 1998;17:1439–1445
  108. Liu A, Du W, Liu JP, et al.  RhoB alteration is necessary for apoptotic and antineoplastic responses to farnesyltransferase inhibitors. Mol. Cell. Biol. 2000;20:6105–6113
  109. Adjei AA, Erlichman C, et al.  A Phase I trial of the farnesyl transferase inhibitor SCH66336: evidence for biological and clinical activity. Cancer Res. 2000;60:1871–1877
  110. Hoover RR, Mahon FX, Melo JV, et al.  Overcoming STI571 resistance with the farnesyl transferase inhibitor SCH66336. Blood. 2002;100:1068–1071
  111. Peters DG, Hoover RR, Gerlach MJ, et al.  Activity of the farnesyl protein transferase inhibitor SCH66336 against BCR/ABL-induced murine leukemia and primary cells from patients with chronic myeloid leukemia. Blood. 2001;97:1404–1412
  112. Crul M, de Klerk GJ, Swart M, et al.  Phase I clinical and pharmacologic study of chronic oral administration of the farnesyl protein transferase inhibitor R115777 in advanced cancer. J. Clin. Oncol. 2002;20:2726–2735
  113. Karp JE, Lancet JE, Kaufmann SH, et al.  Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial. Blood. 2001;97:3361–3369
  114. Fukazawa H, Uehara Y. U0126 reverses Ki-ras-mediated transformation by blocking both mitogen-activated protein kinase and p70 S6 kinase pathways. Cancer Res. 2000;60:2104–2107
  115. Frank DA. STAT signaling in the pathogenesis and treatment of cancer. Mol. Med. 1999;5:432–456 ny.com/link/service/journals/00020/bibs/5n7p432.html
  116. Marra F, Choudhury GG, Abboud HE. Interferon-γ-mediated activation of STAT1α regulates growth factor-induced mitogenesis. J. Clin. Invest. 1996;98:1218–1230

PII: S0268-960X(02)00057-7

Blood Reviews
Volume 17, Issue 1 , Pages 15-23 , March 2003

Article Tools

* Image Usage & Resolution